UNSPSC 51292302: Dembrexine

This classification denotes a mucolytic agent with the molecular formula C13H17Br2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4F61F502T5, chemically known as 4,6-dibromo-alpha-(trans-4-hydroxycyclohexylamino)-o-cresol but generally known as dembrexine, which bears US NIH Compound Identifier 72009. European Medicines Agency schedules Dembrexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06961MIG.

UNSPSC 51292302 Dembrexine is a Commodity code under which state and local governments procure pharmaceutical products, though recent activity shows the code is being applied to a broader range of pharmacy and drug-related services than the code name alone suggests. The recent solicitations captured under this code include naloxone procurement, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and exploratory market intelligence on direct-to-manufacturer prescription programs. State and local issuing bodies using this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon). The work spans product procurement, supply chain management through authorized wholesalers, and program design for pharmacy benefit initiatives.

Recent activity concentrates in Florida, Texas, and Minnesota-Oregon. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building and a response deadline of July 26, 2023. Texas HHS Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with a response deadline of April 3, 2026, before launching a formal RFP. Minnesota Department of Administration's MMCAP issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract performance starting July 1, 2026. Vendors must comply with cGMP, Drug Supply Chain Security Act certification, FDA requirements, and maintain relationships with authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson.